Follow-The-Filings

Security · featured owners

IOVA

Iovance Biotherapeutics Inc. COM Equity as of 2026 Q1 among managers we track

  • 1 Owner
  • Max 3.4%
  • $22M
  • 1 reduce 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 3.4% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors reduce 3.4%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
Palo Alto Investors 2026 Q1 3.4% Reduce −10.8% 6,349,563 $22M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 26,000 $91K hist

1 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $1.19M $164.07M $263.5M
Gross profit * -$9.57M $40.08M $90.32M
Gross margin * -804.5% 24.4% 34.3%
Net income -$444.04M -$372.18M -$390.98M
Net margin * -37345.4% -226.8% -148.4%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $307.85M $457.02M $442.69M
Total non-current assets * $472.5M $453.41M $470.48M
Total assets $780.35M $910.43M $913.17M
Total current liabilities $110.31M $122.34M $138.36M
Total non-current liabilities $85.43M $77.68M $76.23M
Total equity $584.61M $710.4M $698.58M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$361.82M -$352.98M -$302.41M
Cash from investing -$155.24M -$96.41M $47.5M
Cash from financing $462.96M $390.66M $300.77M
Net change in cash -$56.84M -$59.26M $47M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders